ImmunityBio shares surge 10.80% after hours on FDA designations, positive trials, and 467% ANKTIVA sales growth.
ByAinvest
Friday, Nov 28, 2025 4:14 pm ET1min read
IBRX--
ImmunityBio Inc. surged 10.80% in after-hours trading, driven by FDA designations, promising clinical trial results for glioblastoma and non-Hodgkin lymphoma, and a 467% year-to-date sales increase for its bladder cancer therapy ANKTIVA. Recent news highlighted growing patient preference for immunotherapy due to fewer side effects, bolstering investor confidence in the company’s market position. Strong financial results, including $75M in sales and ongoing trial advancements, further fueled optimism about future growth prospects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet